Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT02489513 | Study to Investigate the Absorption, Metabolism, and Excretion of [14C]-AG-120 | PHASE1 | COMPLETED | 8 | — | — | Jun 1, 2015 | Oct 1, 2015 | Dec 14, 2015 | 1 | United States |
Total \[14C\]-radioactivity in whole blood and plasmafollowing oral administration of a single 500-mg (approximately 200 μCi) radiolabeled dose of AG-120 in male subjects
time of maximum observed drug concentration
Area under the curve
Estimate of the terminal elimination half-life
Total \[14C\]-radioactivity in urine, and feces (and vomitus, if applicable).
| Arm | Type | Description |
|---|---|---|
| Single group assignment | OTHER | \[14C\]-AG-120 |
| Name | Type | Description |
|---|---|---|
| [14C]-AG-120 | DRUG | Labeled investigational drug |
Inclusion Criteria: 1. Is a healthy adult male of any race and aged 18 to 55 years, inclusive, at the time of signing the Informed Consent Form (ICF) 2. Understands and voluntarily signs an ICF before any study-related assessments/procedures are conducted 3. Is willing and able to adhere to the stu...